

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



微創醫療科學有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 00853)

ADOPTION OF SUBSIDIARY SHARE OPTION SCHEME

The board of directors (the “**Board**”) of MicroPort Scientific Corporation (the “**Company**”) announces that Shanghai MicroPort EP MedTech Co., Ltd. (上海微創電生理醫療科技股份有限公司) (the “**Subsidiary**”), a 81.93% owned subsidiary of the Company, plans to adopt a share option scheme (the “**Subsidiary Share Option Scheme**”) in order to provide the grantees of the Subsidiary Share Option Scheme with the opportunity to acquire proprietary interests in the Subsidiary, which will encourage the grantees to work towards enhancing the values of the Subsidiary and in turn benefiting the Company and its shareholders as a whole.

The Subsidiary is engaged in the electrophysiology devices business.

The Subsidiary Share Option Scheme is subject to, among other things, the approval of the shareholders of the Company (the “**Shareholders**”) at a general meeting of the Company.

The Company proposes to put forward the proposal for the adoption of the Subsidiary Share Option Scheme at the next annual general meeting of the Company (the “**AGM**”). A circular containing further details about the Subsidiary Share Option Scheme and a notice for the AGM will be despatched to the shareholders of the Company in due course.

By Order of the Board
MicroPort Scientific Corporation
Dr. Zhaohua Chang
Chairman

Shanghai, the PRC, 23 January 2017

As at the date of this announcement, the executive Director is Dr. Zhaohua Chang; the non-executive Directors are Mr. Norihiro Ashida, Mr. Hiroshi Shirafuji, Ms. Weiwei Chen, Ms. Janine Junyuan Feng; and the independent non-executive Directors are Mr. Jonathan H. Chou, Dr. Guoen Liu, and Mr. Chunyang Shao.